1
|
Chikkanna D, Satyam LK, Pnaigrahi SK, Khairnar V, Pothuganti M, Kaza LN, Kalidindi NR, Nataraj VS, Gatta AK, Krishnamurthy NR, Patil S, Samiulla DS, Aithal K, Ahuja VK, Tiwari NK, Charamannna KB, Pise P, Anthony T, Nellore K, Giri S, Chelur S, Samajdar S, Ramachandra M. Abstract 1266: Discovery and preclinical evaluation of a novel covalent inhibitor of FABP5 for cancer therapy. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Dysregulated fatty acid metabolism is thought to be a hallmark of cancer, wherein fatty acids function both as an energy source and as signals for enzymatic and transcriptional networks contributing to malignancy. Fatty acid-binding protein 5 (FABP5) is an intracellular protein that facilitates transport of fatty acids and plays a role in regulating the expression of genes associated with cancer progression such as cell growth, survival, and metastasis. Overexpression of FABP5 has been reported to contribute to an aggressive phenotype and a poor survival correlation in several cancers. Therefore, inhibition of FABP5 is considered as a therapeutic approach for cancers. Phenotypic screening of a library of covalent compounds for selective sensitivity of cancer cells followed by medicinal chemistry optimization resulted in the identification of AUR104 with desirable properties. Chemoproteomic-based target deconvolution revealed FABP5 as the cellular target of AUR104. Covalent adduct formation with Cys43 of FABP5 by AUR104 was confirmed by mass spectrometry. Target occupancy studies using a biotin-tagged AUR104 demonstrated potent covalent binding to FABP5 in both cell-free and cellular conditions. Ligand displacement assay with a fluorescent fatty acid probe confirmed the competitive binding mode of AUR104 with fatty acids. Binding at the fatty acid site and covalent bond formation with Cys43 were also demonstrated by crystallography. Furthermore, AUR104 showed a high degree of selectivity against a broad safety pharmacology panel of enzymes and receptors. AUR104 exhibited potent anti-proliferative activity in a large panel of cell lines derived from both hematological and solid cancers with a high degree of selectivity over normal cells. Anti-proliferative activity in lymphoma cell lines correlated with inhibition of MALT1 pathway activity, cleavage of RelB/Bcl10 and secretion of cytokines, IL-10 and IL-6. AUR104 displayed desirable drug-like properties and dose-dependent oral exposure in pharmacokinetic studies. Oral dosing with AUR104 resulted in dose-dependent anti-tumor activity in DLBCL (OCI-LY10) and NSCLC (NCI-H1975) xenograft models. In a repeated dose MTD studies in rodents and non-rodents, AUR104 showed good tolerability with an exposure multiple of >500 over cellular EC50 for up to 8 hours. In summary, we have identified a novel covalent FABP5 inhibitor with optimized properties that showed anti-tumor activity in in vitro and in vivo models with acceptable safety profile. The data presented here strongly support clinical development of AUR104.
Citation Format: Dinesh Chikkanna, Leena Khare Satyam, Sunil Kumar Pnaigrahi, Vinayak Khairnar, Manoj Pothuganti, Lakshmi Narayan Kaza, Narasimha Raju Kalidindi, Vijaya Shankar Nataraj, Aditya Kiran Gatta, Narasimha Rao Krishnamurthy, Sandeep Patil, DS Samiulla, Kiran Aithal, Vijay Kamal Ahuja, Nirbhay Kumar Tiwari, KB Charamannna, Pravin Pise, Thomas Anthony, Kavitha Nellore, Sanjeev Giri, Shekar Chelur, Susanta Samajdar, Murali Ramachandra. Discovery and preclinical evaluation of a novel covalent inhibitor of FABP5 for cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1266.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Sandeep Patil
- Aurigene Discovery Technologies Ltd, Bangalore, India
| | - DS Samiulla
- Aurigene Discovery Technologies Ltd, Bangalore, India
| | - Kiran Aithal
- Aurigene Discovery Technologies Ltd, Bangalore, India
| | | | | | | | - Pravin Pise
- Aurigene Discovery Technologies Ltd, Bangalore, India
| | | | | | - Sanjeev Giri
- Aurigene Discovery Technologies Ltd, Bangalore, India
| | - Shekar Chelur
- Aurigene Discovery Technologies Ltd, Bangalore, India
| | | | | |
Collapse
|
2
|
Abbineni C, Satyam LK, Kuila B, Ettam A, Rawoof KA, MR S, Dukare SV, Gore ST, Nankar RP, Ahuja VK, KB C, Goyal M, Aithal K, DS S, Mukherjee S, Antony T, Giri S, Chelur S, Nellore K, Daginakatte G, Ramachandra M, Samajdar S. Abstract 1144: Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: SMARCA2 (BRM) and SMARCA4 (BRG1) are two mutually exclusive DNA-dependent ATPases of the SWI/SNF complex, which function in mobilizing nucleosomes to regulate transcription, DNA replication/repair and chromosome dynamics. SMARCA4 is known to be mutated in number of cancers lacking targetable oncogenes, with SMARCA4-mutant patient population representing 10%-20% of NSCLC, 100% small cell ovarian cancer (hypercalcemic type), 28% skin cancer, 16% glioma and 14% colon cancer. Genetic studies have established the necessity of SMARCA2 for survival of tumor cells lacking SMARCA4. Although genetic silencing of SMARCA2 leads to potent anti-proliferative activity in SMARCA4-deficient cancer cell lines, pharmacological studies with a probe capable of binding to SMARCA2 and SMARCA4 bromodomains have failed to recapitulate such anti-proliferative effects. This prompted us to evaluate targeted protein degradation as an alternate approach to target SMARCA4 altered cancers.
Methods and Results: A variety of hetero bi-functional molecules were synthesized by conjugating selective SMARCA2/4 bromodomain inhibitors with either VHL or CRBN E3-ligase specific ligands. Rational design approach guided by our proprietary ternary complex modeling algorithm, ALMOND (ALgorithm for MOdeling Neosubstrate Degraders) resulted in the identification of highly selective SMARCA2 degraders. The lead compound, AU-19820 showed > 10000-fold selectivity for SMARCA2 degradation versus other homologous proteins in tested cell lines. AU-19820 demonstrated potent anti-proliferative activity in SMARCA4 mutant but not in SMARCA2/4 proficient cell lines. This compound displayed favorable IV PK profile in rodents along with clean CYP profile. Additionally, the lead compound exhibited significant tumor growth inhibition in RERF-LC-A1 (SMARCA4 mutant lung cancer) xenograft model when dosed via i.v. route. Efficacious exposures were well tolerated with excellent tumor penetration. The compound also demonstrated moderate oral bioavailability in mouse. Efforts are in progress to improve this further by SAR modifications and exploiting prodrug approach.
Conclusions: Potent and extremely selective SMARCA2 protein degraders were identified by conjugating SMARCA2/4 inhibitors with known VHL or CRBN ligands. SMARCA2 vs SMARCA4 selectivity handles have been very well explored with expandable SAR. Lead compound also displayed a synthetic lethality phenotype in SMARCA4 mutant cancer models while sparing SMARCA2/4 proficient ones. Further optimization of the oral bioavailability and evaluation of efficacy through oral route as well as intermittent IV dosing are planned.
Citation Format: Chandrasekhar Abbineni, Leena Khare Satyam, Bilash Kuila, Ashok Ettam, Khaji Abdul Rawoof, Sreevidya MR, Sandeep Vitthal Dukare, Suraj T. Gore, Rakesh P. Nankar, Vijay Kamal Ahuja, Charamanna KB, Megha Goyal, Kiran Aithal, Samiulla DS, Subhendu Mukherjee, Thomas Antony, Sanjeev Giri, Shekar Chelur, Kavitha Nellore, Girish Daginakatte, Murali Ramachandra, Susanta Samajdar. Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1144.
Collapse
Affiliation(s)
| | | | - Bilash Kuila
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Ashok Ettam
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Sreevidya MR
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Suraj T. Gore
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | | | - Charamanna KB
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Megha Goyal
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Kiran Aithal
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Samiulla DS
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Thomas Antony
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Sanjeev Giri
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Shekar Chelur
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | | | | | | |
Collapse
|
3
|
Srivastava M, Chandra A, Agarwal J, Rahul R, Nigam J, Parmar D, Satyam LK. Antibacterial spectrum of human omentum and differential expression of beta defensins. Indian J Gastroenterol 2019; 38:303-309. [PMID: 31643029 DOI: 10.1007/s12664-019-00981-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2018] [Accepted: 07/23/2019] [Indexed: 02/04/2023]
Abstract
BACKGROUND Human β defensins (hBD1 and hBD2) are cationic, cysteine-rich peptides and form an integral part of the mammalian innate immune system. hBD1 is constitutively expressed in epithelial cells, whereas hBD2 increases in response to bacterial infection. Human omentum is known for its anti-inflammatory properties and also possesses an antibacterial activity of its own. We hypothesized that antimicrobial peptides, β defensins, may govern host defense mechanism in the microbe-rich environment of the peritoneal cavity. Therefore, we analyzed the expression of hBD1 and hBD2 in omentum tissue in vivo and also studied the antibacterial activity of omentum against common pathogens. METHODOLOGY Omentum tissues were obtained from 30 patients (15 cases and 15 controls). Real-time polymerase chain reaction (PCR) was used to evaluate the mRNA expression of hBD1 and hBD2. Protein quantification was done using Western blotting technique. Antibacterial susceptibility was performed to check the antibacterial activity of omentum. RESULT Significantly higher expression of hBD2 was observed in cases compared to controls at both the transcriptional and translational levels. In comparison with an array of antibiotics, activated omentum also showed antibacterial property even at lower concentration of its extract. CONCLUSION Omentum directly responds to bacterial infection, which may be due to differential expression of hBD1 and hBD2 in human omental tissue. These peptides (hBD1 and hBD2) may be an ideal candidate for novel antibiotic class with a broad-spectrum activity.
Collapse
Affiliation(s)
- Meenu Srivastava
- Department of Surgical Gastroenterology, King George's Medical University, Lucknow, 226 003, India
| | - Abhijit Chandra
- Department of Surgical Gastroenterology, King George's Medical University, Lucknow, 226 003, India.
| | - Jyotsna Agarwal
- Department of Microbiology, King George's Medical University, Lucknow, 226 003, India
| | - Rahul Rahul
- Department of Surgical Gastroenterology, King George's Medical University, Lucknow, 226 003, India
| | - Jaya Nigam
- Department of Surgical Gastroenterology, King George's Medical University, Lucknow, 226 003, India
| | - Devendra Parmar
- Developmental Toxicology Division, Indian Institute of Toxicology Research, Lucknow, 226 001, India
| | - Leena Khare Satyam
- Cell and Molecular Biology Department, Aurigene Discovery Technologies Limited, Bangalore, 560 100, India
| |
Collapse
|
4
|
Satyam LK, Sasmal S, Pothuganti MK, M.R. S, Ettam A, Nunna S, Roshaiah M, Chithaluru S, Pallepati R, Pawar AA, Narukulla LP, Sripathi RA, Tgore S, Nankar RP, KB C, S NG, Aithal K, DS S, Mukherjee S, Chelur S, Nellore K, Daginakatte G, Ramachandra M, Samajdar S. Abstract 3844: Anti-tumor efficacy of SMARCA degraders in pre-clinical models of cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
SMARCA2/BRM and SMARCA4/BRG1 are the mutually exclusive DNA-dependent ATPases within the SWI/SNF complexes, which function in mobilizing nucleosomes to regulate transcription, DNA replication and repair, and higher-order chromosome dynamics. SMARCA4 is mutated in a number of cancers, which generally lack targetable oncogenes. Genetic silencing studies have established a requirement of SMARCA2 for survival of tumor cells lacking SMARCA4. SMARCA4-deficient patient population represents 10%-20% of NSCLC cases, ∼5% pancreatic cancer patients and ∼10% ovarian cancer patients where SMARCA2 is overexpressed. Interestingly, SMARCA4 is highly expressed without mutation in certain tumor types, where overexpression contributes to increased proliferation and survival. SMARCA4 knockdown in these tumors leads to inhibition of proliferation and also increase sensitivity to known chemotherapeutic agents, supporting the validity of targeting SMARCA4. Although genetic silencing of SMARCA2 leads to potent anti-proliferative activity in SMARCA4-deficient cancer cell lines, pharmacological studies with a probe capable of binding to SMARCA2 and SMARCA4 bromodomain have failed to show such an anti-proliferative phenotype. These findings triggered us to evaluate chemical degradation as an alternate approach to target SMARCA2/4 altered cancers. Optimization of bifunctional molecules with binding moieties for SMARCA2/4 and E3 ligase to induce proteasome-mediated degradation resulted in the identification of selective SMARCA2 and SMARCA4 degraders. These degraders showed selectivity against other bromodomain containing proteins such as BRD4, CBP and p300 in Western blot analysis. Functional analysis of a preferential SMARCA2 degrader in a panel of cell lines indicated a potent anti-proliferative activity in the context of SMARCA4 mutation. Additionally, these compounds displayed acceptable drug-like properties including solubility, metabolic stability and pharmacokinetics in mice. Dose-dependent tumor growth inhibition was observed in a SMARCA4-deficient lung cancer xenograft model and a syngeneic model of lymphoma at well-tolerated doses. Observed efficacy was correlated with the target degradation in the tumor supporting the potential to further develop them for cancer therapy. Based on the reported vulnerability of SMARCA4-deficient cell lines of diverse tumor origin to agents targeting PARP, PI3K/AKT and EZH2, combination effects with SMARC2 degrader are being interrogated.
Citation Format: Leena Khare Satyam, Sanjita Sasmal, Manoj K. Pothuganti, Sreevidya M.R., Ashokk Ettam, Sireesha Nunna, Marla Roshaiah, Shankaraiah Chithaluru, Rangarao Pallepati, Amitkumar A. Pawar, Leela P. Narukulla, Raghunadh A. Sripathi, Suraj Tgore, Rakesh P. Nankar, Charamanna KB, Nagesh Gowda S, Kiran Aithal, Samiulla DS, Subhendu Mukherjee, Shekar Chelur, Kavitha Nellore, Girish Daginakatte, Murali Ramachandra, Susanta Samajdar. Anti-tumor efficacy of SMARCA degraders in pre-clinical models of cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3844.
Collapse
Affiliation(s)
| | | | | | | | - Ashokk Ettam
- 2Aurigene Discovery Technologies Ltd., Hyderabad, India
| | | | | | | | | | | | | | | | - Suraj Tgore
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Charamanna KB
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Kiran Aithal
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Samiulla DS
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Shekar Chelur
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | | | | | | |
Collapse
|
5
|
Chandra A, Nigam J, Goel M, Parmar D, Satyam LK. Expression and heterodimerization of Type A and B Cholecystokinin Receptors in Gallbladder cancer. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e15655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15655 Background: Gallbladder cancer is the most common malignancy of the biliary tract and endemic in Northern India. The prognosis of gallbladder cancer remains dismal despite any treatment because of late presentation and aggressive tumor biology. Cholecystokinin (CCK) is present in abundance in gallbladder tissue and mediates function through two structurally related receptors, the type A (CCKAR) and B (CCKBR) receptors. Previously, heterodimerization of CCKAR and CCKBR receptor has been demonstrated in vitro, and was shown to bind natural agonists normally but exhibited agonist stimulated cellular signaling, promoting cell growth. In this study we examined the expression level of CCKAR and CCKBR in resected gallbladder tissue samples and also attempted to determine the dimerization status of CCKAR and CCKBR receptors in gallbladder cancer comparing them to cholelithiasis and normal gallbladder tissue. Methods: Tissue samples from resected normal gallbladder (n = 10), cholelithiasis (n = 25) and gallbladder cancer (n = 25)) were evaluated for the expression of CCKAR and CCKBR by immunohistochemistry. Determination of CCKAR and CCKBR expression was also done by western blot in representative samples from each of these tissue types while their dimerization status was evaluated by immunoprecipitation. Results: By Immunohistochemistry technique, positive CCKAR expression was observed in 80% gallbladder cancer, 84% cholelithiasis, 90% normal gallbladder, P = 0.76. However significantly higher expression of CCKBR was noted in gallbladder cancer (60%) as compared to cholelithiasis (25%) and normal gallbladder (20%), P = 0.013. We also observed progressively increasing level of expression of CCKAR and CCKBR in gallbladder cancer as compared to cholelithiasis and normal gallbladder by western blot. In addition, we also observed a higher level of heterodimer formation in gallbladder cancer compared to cholelithiasis and normal gallbladder using immunoprecipitation technique. Conclusions: Our results provide the first evidence of increasing trend of heterodimerization of CCKAR and CCKBR in gallbladder cancer which has potential clinical and therapeutic significance.
Collapse
Affiliation(s)
- Abhijit Chandra
- Department of Surgical Gastroenterology, King George's Medical University, Lucknow, UP, India
| | - Jaya Nigam
- Department of Surgical Gastroenterology King George's Medical University, Lucknow, India
| | | | | | | |
Collapse
|
6
|
Satyam LK, Chikkanna D, Khairnar V, Pothuganti M, Panigrahi S, Lakshminarasimhan A, Rao N, Balasubramanian W, Patil S, Gopinath S, Upendra G, Nagaraj J, Aithal K, Ahuja V, Giri S, Pandit C, Ramachandra M. Abstract 5108: Potent small molecule compounds that selectively inhibit proliferation of ABC-DLBCL cell lines. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-5108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Diffuse large B cell lymphoma (DLBCL), which accounts for 25% of all lymphomas cases, has been classified into molecular subtypes including germinal center B cell like (GCB) DLBCL, activated B cell-like (ABC) DLBCL, and primary mediastinal B cell lymphoma (PMBL). Among these subtypes, patients with ABC-DLBCLs have the worst prognosis because of the high chemo-resistance, and require effective therapies.
Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 (MALT1) protease activity is linked to the pathogenesis of ABC-DLBCL. Therefore, a focused library of covalent compounds selected based on molecular docking on the reported crystal structure was screened for selective sensitivity to ABC-DLBCL, but not GCB-DLBCL cell lines. Optimization of initial hits resulted in the identification of lead compounds with an anti-proliferative EC50 of <100 nM selectively in ABC-DLBCL cell lines. Consistent with the previously reported role of MALT1 inhibitors, lead compounds also showed anti-proliferative activity in selected melanoma and NSCLC cell lines. The anti-proliferative activity of the lead compounds correlated well with the inhibition IL-6, a downstream marker of MALT1 signaling, in ABC-DLBCL cell line such as OCI-LY3. The lead compounds exhibited excellent drug-like properties including solubility, metabolic stability, lack of CYP inhibition, permeability and desired dose-dependent oral exposure in pharmacokinetic studies. In a repeated dose MTD study, the lead compounds showed good tolerability with an exposure multiple of >10 over cellular EC50 for up to 8 hours. The lead compounds showed dose-dependent tumor growth inhibition in a xenograft model upon oral dosing.
In summary, we have identified novel and potent MALT1 inhibitors capable of selectively inhibiting proliferation of DLBCL cell lines with optimized drug-like properties including oral bioavailability. The data presented here strongly support further development of these compounds for DLBCL and other indications.
Citation Format: Leena Khare Satyam, Dinesh Chikkanna, Vinayak Khairnar, Manoj Pothuganti, Sunil Panigrahi, Anirudha Lakshminarasimhan, Narasimha Rao, Wesley Balasubramanian, Sandeep Patil, Sreevalsam Gopinath, Gunta Upendra, Jwala Nagaraj, Kiran Aithal, Vijay Ahuja, Sanjeev Giri, Chetan Pandit, Murali Ramachandra. Potent small molecule compounds that selectively inhibit proliferation of ABC-DLBCL cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5108. doi:10.1158/1538-7445.AM2017-5108
Collapse
Affiliation(s)
| | | | | | | | | | | | - Narasimha Rao
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Sandeep Patil
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Gunta Upendra
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Jwala Nagaraj
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Kiran Aithal
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Vijay Ahuja
- 2Aurigene Discovery Technologies Ltd., Hyderabad, India
| | - Sanjeev Giri
- 2Aurigene Discovery Technologies Ltd., Hyderabad, India
| | - Chetan Pandit
- 1Aurigene Discovery Technologies Ltd., Bangalore, India
| | | |
Collapse
|
7
|
Satyam LK, Chikkanna D, G AK, Khairnar VV, Reddy S, Durgaprasad V, Radhakrishna K, Panigrahi SK, Ramanathan A, Mahasweta K, Lakshminarasimhan A, K NR, R V, Gopinath S, Kumar S, Shah MH, Ramachandra R, B KA, Pandit C, Ramachandra M. Abstract 339: Identification of novel covalent inhibitors of K-Ras G12C that are efficacious in a xenograft model of NSCLC. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
KRAS is the frequently mutated isoform in RAS driven cancers. The G12C mutation is more predominantly associated with various tumor types over other changes in K-Ras. Although direct targeting of RAS is very challenging, it is possible to selectively target G12C mutant K-Ras using a covalent approach. Mutant specific covalent inhibitors with high selectivity against wild type K-Ras and other GTPases are expected to lead to efficacy with a very high degree of tolerability. Here, we report identification of lead compounds from two distinct chemical series that selectively target K-Ras G12C. Molecular modeling based on the reported crystal structures aided in the identification of these compounds. Covalent binding of the lead compounds to K-Ras G12C was demonstrated by MALDI-TOF. Lead compounds were potent in selectively inhibiting proliferation of cell lines with K-Ras G12C mutation but not with wild type K-Ras. The anti-proliferative activity of the lead compounds correlated well with their potency in a cellular mechanistic assay. Lead compounds from both series exhibited excellent drug-like properties including solubility, metabolic stability, permeability lack of CYP inhibition and desired exposure in pharmacokinetic studies. In a xenograft model of NSCLC, the lead compound demonstrated dose-dependent tumor growth inhibition with excellent tolerability upon oral dosing. In summary, we have identified a novel, potent and selective K-Ras G12C inhibitor with optimized drug-like properties including oral bioavailability and efficacy in a NSCLC derived xenograft model. Toxicity evaluation is ongoing towards progressing the lead compound to the clinic.
Citation Format: Leena Khare Satyam, Dinesh Chikkanna, Aswani K. G, Vinayak V. Khairnar, Sreekanth Reddy, Vakkapatla Durgaprasad, Kowju Radhakrishna, Sunil K. Panigrahi, Anuradha Ramanathan, Kumari Mahasweta, Anirudha Lakshminarasimhan, Narasimha R. K, Vinutha R, Sreevalsam Gopinath, Suryakant Kumar, Mubarak H. Shah, Raghuveer Ramachandra, Kiran A. B, Chetan Pandit, Murali Ramachandra. Identification of novel covalent inhibitors of K-Ras G12C that are efficacious in a xenograft model of NSCLC. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 339.
Collapse
Affiliation(s)
| | | | - Aswani K. G
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | | | | | | | | | | | | | | | | | - Vinutha R
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | | | | | | | - Kiran A. B
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Chetan Pandit
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | |
Collapse
|